INSTITUTIONAL BIOSAFETY COMMITTEE MEETING  
January 18, 2017  
3 PM, 410 Plant Biotechnology Building

MEMBERS PRESENT: Chair, Jun Lin; Tamara Chavez-Lindell, Paul Dalhaimer, Doris D’Souza, Reza Hajimorad, Al Iannacone, Brittany Isabell, Elizabeth Fozo, Melissa Kennedy, Ling Zhao

Ex-Officio –Linda Hamilton, Scott Moser, Brian Ranger, Jessica Woofter

MEMBERS ABSENT: Seung Baek, David Bemis, Patti Coan, Reggie Millwood, Deidra Mountain, Jae Park

OTHERS PRESENT: None

Opening:

The meeting was called to order by the Chair, Jun Lin at 3:01 PM. The minutes of December 7, 2016 were reviewed and approved pending minor typographical corrections. There was one abstention.

IBC Applications:

#448 (Budke) Recombinant DNA Registration, III-E-2-a, New Registration
Dr. Budke’s research involves the generation of 2-fluroadenine (2-FA) resistant *Physcomitrella patens* (spreading earth moss). This will be achieved by utilizing the new genetic engineering technique CRISPR-Cas9. If the CRISPR-Cas9 genome editing strategy is successful in *P. patens*, then it may be used in future genetic studies. The containment level was established at BSL-1. The committee voted to approve the registration pending clarification of fluroadenine resistance in the nontechnical summary and citation formatting in the technical summary.

Old Business:

Administrative Report

i. Administrative Approvals
Brian Ranger provided the committee with the administrative report. Following up on December 7, 2016, IBC meeting, Dr. Stephen Kania’s registration (#411-16) was corrected administratively (minor clarifications). Dr. Colleen Jonsson’s amendment (#434) to include diagnostic screening of tissues derived from shrews, moles, and bats for presence of hantaviruses was approved administratively by the IBC Chair. Dr. Faith Critzer’s amendment to (#399-16) to move the management of infectious stocks and the laboratory (FSP 25) previously held by Dr. David Golden (#299-16) was approved administratively by the Biosafety Officer.

ii. Administrative Terminations
Dr. David Golden’s registration (#299-16) was administratively terminated and all remaining infectious stocks and laboratory space was transferred to Dr. Faith Critzer per departmental arrangements.

iii. Accidents, Injuries/Exposures:
There were no accidents or exposures to report for this month.

**iv. Laboratory Report**

There were no new laboratory findings to report for this month.

**iMedRIS Update**

Jessica Woofter notified the committee that the iMedRIS amendment and annual update forms are in the revision process. The Biosafety Office will be meeting next week to discuss revisions. IBC training will begin in March and PIs will be required to start using the new system in July.

**Refresher Training Updates**

Linda reported that the training content is completed and is in the process of being loaded into Qualtrics. The Biosafety Office chose the Qualtrics platform because it is easy to populate trainees and a certificate is issued via email upon completion. 675 participants have been emailed and of those 129 have started the training and 115 have completed the training in the first week.

**CDC Inspection for Jonsson Laboratories: Findings & Corrective Actions**

Brian notified the committee that the CDC Import Permit inspection of Dr. Jonsson’s BSL-2 and BSL-3 laboratories was successful overall. Only two minor departures were noted and easily remedied.

**Environmental Release of Recombinant Raccoon Pox Virus-Vectored Vaccine**

Brian notified the committee that we received a response from NIH OSP regarding the recombinant raccoon pox virus release. The only additional follow-up is the submission of the joint IBC/IACUC policy covering clinical trials at CVM (pending committee approvals).

**Mandatory Glove Use in BSL-2 Laboratories (Continued Discussion)**

Brian suggested that gloves should be worn when handling potential biohazards in BSL-2 laboratories. Exceptions to this default practice are to be documented in a SOP. Brian also notified the committee that a new FDA rule has banned the use of powdered surgical or examination gloves, effective immediately.

**New Business:**

**Joint IBC/IACUC Policy on Recombinant DNA Use in Veterinary Clinical Trials**

Brian notified the committee that he will be working Dr. Lori Cole and the IACUC to establish a joint IBC/IACUC Policy concerning the use of rDNA in veterinary clinical trials. Brian asked for any comments or corrections so we can sent out to NIH by February. The committee recommending adding definitions for “containment” and “release” as well as contact information for Biosafety Office.

**College of Veterinary Medicine – Safety Task Force**

Brian notified the committee that College of Veterinary Medicine had issued a 7-year strategic plan. To address safety and safety culture improvements, Dean Thompson commissioned a task force comprised of Brian Ranger, Jacob Payne, Aly Chapman, Dr. Melissa Hines, Janet Jones, and Dr. Amy Knowles. The task force completed a physical space walkthrough of clinical, research and support areas of CVM, reviewed existing policies and procedures, reviewed accident/injury reports and trends from the previous 5 years, and solicited feedback from staff and students. Findings were compiled into a report and submitted to the Dean and Executive Committee for consideration.

**Relocation of Biosafety Office**

Brian announced to the committee that the Biosafety Office will be moving in late April early May (tentatively) to Melrose Ave on the UTK campus. The move will take place once requested
renovations have been completed.

Medical Waste Contractor – RFP Update

Brian was appointed to chair the technical review committee for a new regulated medical waste RFP. Based on the technical review as well as the cost analysis by Procurement Services, the contract (for UTK, UTIA, and UTC) was awarded to Advantra, Inc. (Atlanta, GA).

The meeting was adjourned at 4:01 PM. The next meeting is tentatively scheduled for February 15, 2017 starting at 3 pm.